Company news
Poolbeg Pharma PLC news in 2022
Poolbeg Pharma PLC's news releases, calls and decks from 2022, newest first.
Poolbeg Pharma identifies new RSV drug candidates
December 22, 2022
Poolbeg identifies novel RSV drug candidates
December 21, 2022
Poolbeg Pharma makes 'interesting addition to e...
December 15, 2022
Metabolic diseases oral delivery licence signed
December 14, 2022
Poolbeg Pharma receives initial results from hu...
December 12, 2022
POLB 001 LPS human challenge trial completed
December 12, 2022
Influenza AI model build completed
November 29, 2022
Poolbeg Pharma wins first non-dilutive grant fu...
November 21, 2022
Capital Markets Day
November 17, 2022
Poolbeg-led consortium awarded EUR 2.3m grant
November 15, 2022
Poolbeg Pharma makes virus 'breakthrough' using...
November 9, 2022
AI programme yields novel RSV drug targets
November 8, 2022
Upcoming events participation
October 21, 2022
CEO Share Purchase
October 6, 2022
POLB 001 US Patent update
October 4, 2022
Poolbeg licence of Melioidosis vaccine candidate
September 21, 2022
HC Wainwright Global Investment Conference
September 12, 2022
Interim Results
September 6, 2022
Notice of Results
August 31, 2022
POLB001 human challenge clinical trial to commence
July 20, 2022
Project update for AI model of RSV data
June 27, 2022
US patents granted for POLB 001 and POLB 002
May 26, 2022
TR-1: Notification of major interest in shares
May 23, 2022
GMP manufacturing contract signed
May 12, 2022
Attendance at European Melioidosis Congress
May 11, 2022
Distribution in Specie update
April 27, 2022
Key POLB 002 European Patent Granted
April 14, 2022
Distribution in Specie Shareholders
April 11, 2022
POLB001 Update - Clinical Trial Agreement Signed
March 31, 2022
Commencement of trading on US OTCQB market
March 30, 2022
AI deal signed with CytoReason
March 24, 2022
Notice of AGM
March 9, 2022
Final Results
March 3, 2022
Artificial Intelligence deal with OneThree Biotech
February 24, 2022
Confirmation of vaccine platform licence execution
January 31, 2022
Exclusive license of RNA-based immunotherapy asset
January 17, 2022